Teleflex Inc

Teleflex Inc(TFX)股票分析

$131.150

+1.482 (+1.13%)收盘时

Loading chart…
最高
131.180
开盘
130.510
成交量加权均价
130.58
成交量
473.05K
市值
9.76B
最低
129.400
成交额
61.77M
企业价值/息税折旧摊销前利润(TTM)
20.97

Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, and vascular access. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of the MANTA Vascular Closure device, Arrow OnControl powered bone biopsy system, GuideLiner, Turnpike and TrapLiner catheters.

AI 分析 of Teleflex Inc (TFX)

买入

Teleflex Inc is a good buy right now, with a current price of $130.43 and a forward P/E of 11.01, indicating potential for growth. The recent upgrade from BofA reflects confidence in the company's new management and execution, which could lead to better-than-expected organic growth. Additionally, the stock has shown a 5-day change of +4.24%, suggesting positive momentum. However, the main risk is the high debt to equity ratio of 96.68%, which could impact financial stability if not managed properly.

分析师评级(12)

上行空间 +3.85%
买入
10 买入
2 持有
0 卖出
当前: 131.15
最低
122.00
平均
136.20
最高
155.00

BofA

2026-09-28

目标价

$158

买入

UBS

2026-08-11

目标价

$158

中性

Truist

2026-08-10

目标价

$150

持有

Raymond James

2026-08-07

目标价

$155

跑赢大盘

Needham

2026-07-31

目标价

$159

买入

估值指标

Teleflex Inc(TFX)当前预期市盈率为 11.01,5 年平均预期市盈率为 15.77。

预期市盈率

合理
5 年均值 P/E
15.77
当前P/E
11.01
高估
20.82
低估
10.71

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
16.05
当前EV/EBITDA
20.97
高估
26.36
低估
5.74

预期市销率

合理
5 年均值 P/S
3.22
当前P/S
2.34
高估
4.36
低估
2.08

Alphio AI 对 TFX 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%TFX

$155.14

情景价格

基

基准

基准 · 50%TFX

$141.18

情景价格

悲

悲观

悲观 · 25%TFX

$135.32

情景价格

持有 TFX 的大户

T

The Baupost Group, L.L.C.

+ 持有TFX

+1.67%

3个月收益率

H

Heartland Advisors, Inc.

+ 持有TFX

+0.25%

3个月收益率

A

Abrams Bison Investments, L.L.C.

+ 持有TFX

-0.90%

3个月收益率

C

Cooke & Bieler, L.P.

+ 持有TFX

-3.50%

3个月收益率

S

Sessa Capital IM, L.P.

+ 持有TFX

-14.11%

3个月收益率

事件时间线

2026-10-12 (ET)

07:00:00

Teleflex Completes Patient Enrollment in BIOMAG-LL Clinical Study

2026-09-29 (ET)

07:00:00

Teleflex Study Shows Arrowg+ard Technology Reduces CLABSI Risk by 70%

2026-09-28 (ET)

17:00:00

Nyxoah Appoints Liam Kelly as CEO

09:00:00

Stock Futures Decline Due to Rising Oil Prices and Treasury Yields

2026-09-04 (ET)

07:30:00

Teleflex Showcases Dynetic-35 Stent Technology at CIRSE 2026 in Copenhagen

资讯

TFX 常见问题 —— 由 Alphio AI 解答

Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, and vascular access. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of the MANTA Vascular Closure device, Arrow OnControl powered bone biopsy system, GuideLiner, Turnpike and TrapLiner catheters. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Teleflex Inc is a good buy right now, with a current price of $130.43 and a forward P/E of 11.01, indicating potential for growth. The recent upgrade from BofA reflects confidence in the company's new management and execution, which could lead to better-than-expected organic growth. Additionally, the stock has shown a 5-day change of +4.24%, suggesting positive momentum. However, the main risk is the high debt to equity ratio of 96.68%, which could impact financial stability if not managed properly.

12 analysts cover TFX: 10 rate it Buy, 2 Hold and 0 Sell. The average price target is 136.20.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易